Eli Lilly and Company (LLY) 44th Annual J.P. Morgan Healthcare Conference summary

Key achievements and portfolio updates

• Celebrated 150th anniversary with strong momentum and expanded certainty in obesity and diabetes portfolio.

• Transitioned from a single-product focus to a broad portfolio, with 13 new sites under construction and global reach.

• Significant manufacturing investments resolved supply shortages, enabling global launches in over 30 major markets.

• LillyDirect platform scaled to serve over 1 million people monthly, expanding direct-to-consumer access globally.

• Investing $55B to create a sustainable advantage, with major manufacturing and research sites in the US and Europe.

Pipeline and therapeutic innovation

• Advanced pipeline with phase III data for orforglipron (oral GLP-1), retatrutide (triple-acting incretin), and new phase III programs for eloralintide and brenipatide.

• Over 34 discovery programs and 6 additional clinical-stage programs, including incretins, amylins, and novel targets.

• More than 75% of new clinical medicines are outside of incretins and amylins, addressing unmet needs in Alzheimer's, breast cancer, and chronic pain.

• Advancing late-phase and launch programs targeting obesity, diabetes, sleep apnea, pain, and cardiovascular diseases.

• Broadened pipeline includes 6 phase I/II programs and 34 preclinical projects targeting obesity and related diseases.

Market access and pricing dynamics

• Expanded access through collaboration with government, including Medicare Part D and Medicaid, with $50 out-of-pocket costs for seniors.

• Commercial access remains uneven, with efforts to improve transparency and offer non-traditional benefit options.

• High self-pay demand observed internationally, with pricing discipline maintained across markets.

• Orforglipron expected to launch at $149 base dose, aiming for broader reach and maintenance therapy use.

• Anticipates high single-digit price deflation in commercial segment, with volume as the key variable for future growth.